SG11201404313YA - Biomarkers and combination therapies using oncolytic virus and immunomodulation - Google Patents

Biomarkers and combination therapies using oncolytic virus and immunomodulation

Info

Publication number
SG11201404313YA
SG11201404313YA SG11201404313YA SG11201404313YA SG11201404313YA SG 11201404313Y A SG11201404313Y A SG 11201404313YA SG 11201404313Y A SG11201404313Y A SG 11201404313YA SG 11201404313Y A SG11201404313Y A SG 11201404313YA SG 11201404313Y A SG11201404313Y A SG 11201404313YA
Authority
SG
Singapore
Prior art keywords
immunomodulation
biomarkers
combination therapies
oncolytic virus
oncolytic
Prior art date
Application number
SG11201404313YA
Other languages
English (en)
Inventor
Frank Tufaro
Charles Conrad
Juan Fueyo-Margareto
Frederick Lang
Candelaria Gomez-Manzano
W K Alfred Yung
Amy Himberger
Original Assignee
Dnatrix Inc
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnatrix Inc, Univ Texas filed Critical Dnatrix Inc
Publication of SG11201404313YA publication Critical patent/SG11201404313YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
SG11201404313YA 2012-01-25 2013-01-25 Biomarkers and combination therapies using oncolytic virus and immunomodulation SG11201404313YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261590441P 2012-01-25 2012-01-25
US201261637191P 2012-04-23 2012-04-23
PCT/US2013/023304 WO2013112942A1 (en) 2012-01-25 2013-01-25 Biomarkers and combination therapies using oncolytic virus and immunomodulation

Publications (1)

Publication Number Publication Date
SG11201404313YA true SG11201404313YA (en) 2014-10-30

Family

ID=47754947

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201404313YA SG11201404313YA (en) 2012-01-25 2013-01-25 Biomarkers and combination therapies using oncolytic virus and immunomodulation
SG10201913784YA SG10201913784YA (en) 2012-01-25 2013-01-25 Biomarkers and combination therapies using oncolytic virus and immunomodulation
SG10201604654RA SG10201604654RA (en) 2012-01-25 2013-01-25 Biomarkers and combination therapies using oncolytic virus and immunomodulation

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201913784YA SG10201913784YA (en) 2012-01-25 2013-01-25 Biomarkers and combination therapies using oncolytic virus and immunomodulation
SG10201604654RA SG10201604654RA (en) 2012-01-25 2013-01-25 Biomarkers and combination therapies using oncolytic virus and immunomodulation

Country Status (11)

Country Link
US (3) US10238698B2 (enExample)
EP (2) EP2806883B1 (enExample)
JP (3) JP2015508156A (enExample)
KR (1) KR102081567B1 (enExample)
CN (1) CN104427992B (enExample)
AU (2) AU2013211871B2 (enExample)
BR (1) BR112014018331A8 (enExample)
CA (1) CA2862390A1 (enExample)
DK (1) DK2806883T3 (enExample)
SG (3) SG11201404313YA (enExample)
WO (1) WO2013112942A1 (enExample)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008007056A (es) 2005-12-02 2008-11-12 Sinai School Medicine Virus quimericos que presentan proteinas de superficie no nativas y usos de los mismos.
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010091262A1 (en) 2009-02-05 2010-08-12 Mount Sinai School Of Medicine Of New York University Chimeric newcastle disease viruses and uses thereof
EP4663241A3 (en) 2010-10-08 2026-03-25 Mesoblast International Sàrl Enhanced msc preparations
US11155599B2 (en) 2012-02-02 2021-10-26 Board Of Regents, The University Of Texas System Adenoviruses expressing heterologous tumor-associated antigens
WO2013131050A1 (en) * 2012-03-02 2013-09-06 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for differential treatment of cancer
US20150118244A1 (en) * 2012-05-10 2015-04-30 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
FI3381942T4 (fi) * 2012-08-30 2025-12-16 Amgen Inc Menetelmä melanooman hoitamiseksi herpes simplex -virusta ja immuuniaktivaation vapauttajaa käyttäen
KR102222157B1 (ko) 2013-03-14 2021-03-03 이칸 스쿨 오브 메디슨 엣 마운트 시나이 뉴캐슬병 바이러스 및 이의 용도
US9945870B2 (en) 2013-05-17 2018-04-17 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
CN104415335A (zh) * 2013-09-02 2015-03-18 北京中康万达医药科技有限公司 体内个体化系统免疫治疗方法和装置
KR20160137946A (ko) * 2013-11-22 2016-12-02 디엔에이트릭스, 인코포레이티드 면역 세포 자극성 수용체 작용제(들)를 발현하는 아데노바이러스
WO2015127501A1 (en) * 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
EP2942629A1 (en) * 2014-05-08 2015-11-11 Universität Würzburg Predictive markers for successful cancer immunotherapy
US20170115291A1 (en) * 2014-05-28 2017-04-27 Dana-Farber Cancer Institute, Inc. Activating JAK Kinase Biomarkers Predictive of Anti-Immune Checkpoint Inhibitor Response
WO2016065330A1 (en) * 2014-10-24 2016-04-28 Aladar Szalay Combination immunotherapy approach for treatment of cancer
WO2016149350A1 (en) * 2015-03-17 2016-09-22 Mayo Foundation For Medical Education And Research Methods and materials for assessing and treating cancer
AU2016256911B2 (en) 2015-05-07 2022-03-31 Agenus Inc. Anti-OX40 antibodies and methods of use thereof
EP4667487A2 (en) 2015-06-03 2025-12-24 Aelan Cell Technologies, Inc. Companion methods and kits for il-2-based therapies and mesenchymal stem cell-based therapies
WO2017013421A1 (en) 2015-07-20 2017-01-26 Virttu Biologics Limited Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood
JP6452266B2 (ja) * 2015-07-22 2019-01-16 国立大学法人鳥取大学 ワクシニアウイルスの増殖・伝搬を増強する宿主制御因子
EA201800148A1 (ru) 2015-08-11 2019-01-31 Калиди Биотерапьютикс, Инк. Оспенная вакцина для лечения рака
JP2018526382A (ja) 2015-09-04 2018-09-13 アスラン ファーマシューティカルズ ピーティーイー リミテッド 耐性癌または難治性癌の治療用バルリチニブ
WO2017062615A2 (en) * 2015-10-08 2017-04-13 Macrogenics, Inc. Combination therapy for the treatment of cancer
US10744170B2 (en) * 2015-10-15 2020-08-18 Duke University Combination treatment
CN106591361A (zh) * 2015-10-20 2017-04-26 钱文斌 一种重组痘溶瘤病毒及其构建方法和应用
CN108367070B (zh) * 2015-11-04 2022-10-28 杜克大学 免疫毒素与检查点抑制剂的组合治疗
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
WO2017118866A1 (en) 2016-01-08 2017-07-13 Replimune Limited Engineered virus
EP3193173A1 (en) * 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Serological autoantibodies as biomarker for colorectal cancer
FI127460B (en) * 2016-01-15 2018-06-29 Targovax Oy Combining adenovirus and chemotherapeutic agents for treating cancer
EP4070812A1 (en) * 2016-01-21 2022-10-12 The Board of Trustees of the Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents
CN105603085B (zh) * 2016-01-29 2019-01-29 北京泱深生物信息技术有限公司 椎间盘退行性病变的诊治靶标
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
MA55153A (fr) * 2016-02-19 2021-09-29 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
ES3041500T3 (en) * 2016-03-10 2025-11-12 Cg Oncology Inc Methods of treating solid tumors by combination therapy
WO2017176289A1 (en) * 2016-04-08 2017-10-12 Celgene Corporation Uses of lenalidomide and car t-cells
GB201608918D0 (en) * 2016-05-20 2016-07-06 Aslan Pharmaceuticals Pte Ltd Method
CN109789177A (zh) * 2016-05-27 2019-05-21 德那翠丝有限公司 腺病毒和免疫调节剂组合治疗
WO2017218757A1 (en) * 2016-06-17 2017-12-21 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN109983121A (zh) 2016-06-30 2019-07-05 昂克诺斯公司 治疗性多肽的假型化溶瘤病毒递送
US20190185571A1 (en) * 2016-07-28 2019-06-20 Musc Foundation For Research Development Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors
CA3040194A1 (en) * 2016-10-13 2018-04-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature
US20190275092A1 (en) 2016-11-01 2019-09-12 Dnatrix, Inc. Combination therapy for treatment of brain cancers
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
CN110381997A (zh) * 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
JP2020504767A (ja) 2016-12-21 2020-02-13 メムゲン，エルエルシー 武装した複製可能な腫瘍溶解性アデノウイルス
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
EP4628895A3 (en) 2017-01-13 2025-12-17 Mayo Foundation for Medical Education and Research Materials and methods for treating cancer
CN108341818A (zh) * 2017-01-21 2018-07-31 南京华威医药科技开发有限公司 巴瑞克替尼及其磷酸盐的新晶型及其制备方法
CN108338994A (zh) * 2017-01-25 2018-07-31 杭州康万达医药科技有限公司 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用
JP2020510444A (ja) * 2017-02-08 2020-04-09 ミトラ アールエックスディーエックス, インコーポレイテッドMitra Rxdx, Inc. 抗がん剤の臨床成果を予測する方法
US20200046696A1 (en) * 2017-02-14 2020-02-13 Celgene Corporation Treatment of cancer with smg1-inhibitors
EP4599893A3 (en) 2017-04-14 2025-11-05 CG Oncology, Inc. Cg0070 for treating bcg resistant bladder carcinoma in situ
MX2019012741A (es) 2017-04-28 2020-01-21 Merck Sharp & Dohme Biomarcadores para agentes terapeuticos contra el cancer.
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
AU2018372631B2 (en) 2017-11-22 2025-06-05 Mesoblast International Sarl Cellular compositions and methods of treatment I
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
EP3740503A1 (en) * 2018-01-17 2020-11-25 Eli Lilly and Company Compounds and methods targeting interleukin-19
CN108414660B (zh) * 2018-03-08 2020-03-20 中国药科大学 一组与肺癌早期诊断相关的血浆代谢小分子标志物的应用
KR20200135986A (ko) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
CN110527696A (zh) * 2018-06-13 2019-12-03 中山大学 一种IFNβ和FerritinH基因联合修饰的骨髓间充质干细胞及其制备方法和应用
KR102091567B1 (ko) * 2018-06-15 2020-03-20 인하대학교 산학협력단 오스테오폰틴 단백질 단편을 유효성분으로 함유하는 뇌손상 예방 또는 치료용 약학 조성물
CN110755619A (zh) * 2018-07-27 2020-02-07 复旦大学 一种人疱疹病毒裂解复制激活的宿主标志物及其用途
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
CN108998529A (zh) * 2018-08-30 2018-12-14 上海交通大学医学院附属上海儿童医学中心 肺腺癌检测试剂盒及检测tulp2基因甲基化水平的方法
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN113271955A (zh) * 2018-11-06 2021-08-17 卡利迪生物治疗有限公司 用于细胞介导的溶瘤病毒疗法的增强的系统
TW202102207A (zh) * 2019-03-27 2021-01-16 新加坡商新加坡保健服務集團有限公司 對於癌病具有治療意義的生物標記
JP7608357B2 (ja) * 2019-03-28 2025-01-06 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ ＶＳＶ－ＩＦＮβ－ＮＩＳ腫瘍溶解療法における薬力学マーカーとしてのＩＦＮβ
KR102199141B1 (ko) 2019-05-03 2021-01-06 사회복지법인 삼성생명공익재단 대장암 진단 마커 및 대장암 진단에 필요한 정보를 제공하는 방법
MX2021013588A (es) 2019-05-08 2022-02-11 Medigene Immunotherapies Gmbh Células t genomodificadas.
JP2022533480A (ja) * 2019-05-24 2022-07-22 エディフィス ヘルス，インコーポレーテッド 癌免疫療法のためのプレシジョンメディシン法
CN114423860A (zh) 2019-08-05 2022-04-29 迈索布拉斯特国际有限公司 包含病毒载体的细胞组合物及治疗方法
CN110687281B (zh) * 2019-08-26 2023-05-23 中国医学科学院肿瘤医院 Pd-l1自身抗体在肿瘤预后评估中的应用
CN114630683A (zh) * 2019-08-29 2022-06-14 拜耳诺克斯有限公司 包含痘苗病毒和粒细胞生成抑制剂作为活性成分的用于治疗癌症的药物组合物
WO2021061775A1 (en) * 2019-09-23 2021-04-01 Sillajen, Inc. Immune assay for monitoring response to oncolytic vaccinia virus and uses thereof
CN111337678B (zh) * 2020-02-21 2023-06-06 杭州凯保罗生物科技有限公司 与肿瘤免疫治疗效果相关的生物标志物及其应用
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
WO2021225422A1 (ko) * 2020-05-08 2021-11-11 주식회사 루닛 병리 슬라이드 이미지에 대한 면역 표현형과 연관된 정보를 제공하는 방법 및 장치
WO2021225421A1 (ko) 2020-05-08 2021-11-11 주식회사 루닛 면역 항암제에 대한 반응을 예측하는 방법 및 시스템
EP4105943A4 (en) * 2020-05-08 2024-03-20 Lunit Inc. Method and system for predicting reaction to immuno-oncology agent
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
CN111579788A (zh) * 2020-05-29 2020-08-25 郑州大学 一种高灵敏肿瘤标志物EPHA2的Simoa试剂盒及其应用
CN115996735A (zh) 2020-08-10 2023-04-21 迈索布拉斯特国际有限公司 细胞组合物和治疗方法
CN116322728A (zh) * 2020-08-14 2023-06-23 上海行深生物科技有限公司 水疱性口炎病毒及其治疗用途
CN112345755B (zh) * 2020-09-23 2023-06-16 杭州凯保罗生物科技有限公司 乳腺癌的生物标志物及其应用
KR102710867B1 (ko) * 2020-12-18 2024-09-27 (주)인비보텍 Oligodendrocyte transcription factor 2 억제제를 유효성분으로 포함하는 흑색종 치료 효과 증진용 약학적 조성물
US20240036045A1 (en) * 2020-12-22 2024-02-01 The Brigham And Women`S Hospital, Inc. Blood-based protein biomarker panel for early and accurate detection of cancer
CN114764101B (zh) * 2021-01-25 2025-08-08 武汉大学中南医院 一种确定具有gbm预后价值的血液炎症标志物的方法及gbm生存率计算系统
EP4444873A4 (en) * 2021-12-06 2026-03-04 Elevatebio Tech Inc Compositions and methods of cancer therapy related to the Seneca Valley Virus (SVV)
JP2025536260A (ja) 2022-10-11 2025-11-05 イェール ユニバーシティー 細胞透過性抗体の組成物および使用方法
CN115948557B (zh) * 2023-01-04 2025-09-02 陕西师范大学 一种nlrp2作为靶点在卵巢癌疾病诊断和/或治疗中的应用
CN120835927A (zh) * 2023-09-28 2025-10-24 复旦大学附属华山医院 用于治疗胶质瘤的组合物

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5981725A (en) 1989-09-08 1999-11-09 The Johns Hopkins Univiersity Structural alterations of the EGF receptor gene in human tumors
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
EP0791050B1 (en) 1994-11-28 2006-02-15 Cell Genesys Inc. Vectors for tissue-specific replication
EP0821739B1 (en) 1995-04-17 2003-06-18 The Board Of Regents, The University Of Texas System An adenovirus helper-virus system
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
US6080578A (en) 1996-12-31 2000-06-27 Onyx Pharmaceuticals, Inc. Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
JP2002514075A (ja) 1997-03-03 2002-05-14 セル ジェネシス，インコーポレイティド 癌胎児性抗原を発現する細胞に特異的なアデノウイルスベクターおよびその使用方法
US6096718A (en) 1997-06-05 2000-08-01 Gene Targeting Corp. Tissue specific adenovirus vectors for breast cancer treatment
JP2002530085A (ja) 1998-11-18 2002-09-17 カンジ，インコーポレイテッド 後期導入遺伝子の発現を有するウイルスベクター
GB9906815D0 (en) 1999-03-24 1999-05-19 Isrec Anti-neoplastic viral agents
US20040175362A1 (en) 1999-05-12 2004-09-09 Curiel David T. Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
US6824771B1 (en) 1999-05-12 2004-11-30 The Uab Research Foundation Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
ATE371031T1 (de) 1999-06-08 2007-09-15 Uab Research Foundation Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
AU1190901A (en) 1999-09-30 2001-04-30 Trustees Of The University Of Pennsylvania, The Replication selective adenoviruses for use in cancer therapy
CA2386626A1 (en) 1999-10-15 2001-04-26 Richard Murphy Targeted vectors
US6740525B2 (en) 2000-02-09 2004-05-25 Genvec, Inc. Adenoviral capsid containing chimeric protein IX
US6756044B1 (en) 2000-02-09 2004-06-29 Genvec, Inc. Antigenic complexes and methods
US20030138405A1 (en) 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
US20030211477A1 (en) 2002-04-05 2003-11-13 Holmes Kathryn V. Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening
US7736644B2 (en) 2003-06-27 2010-06-15 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US20070134202A1 (en) * 2003-10-15 2007-06-14 The New Industry Reserch Organization Cancer gene therapeutic drug
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
CA2563103C (en) * 2004-03-31 2015-02-17 Tomoki Todo Enhancer of anticancer activity in viral therapy and method of preventing or treating cancer
CN101098877A (zh) 2004-07-13 2008-01-02 不列颠哥伦比亚大学 吲哚胺-2,3-双加氧酶(ido)抑制剂
ES2605380T3 (es) 2005-05-06 2017-03-14 Providence Health & Services - Oregon Proteina de fusión OX40-inmunoglobulina trimérica y métodos de uso
CA2612241C (en) * 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
AU2006287052B2 (en) * 2005-08-31 2009-03-12 Oncolytics Biotech Inc. Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms
US20070292396A1 (en) * 2006-03-02 2007-12-20 Juan Fueyo Combination therapy with oncolytic adenovirus
WO2009117656A2 (en) 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
JP2012513209A (ja) 2008-12-22 2012-06-14 オンコス セラピュティックス オサケ ユキチュア 腫瘍溶解アデノウイルスベクター並びに前記に関連する方法および使用
CN101607985B (zh) 2008-12-24 2013-03-27 中国科学院生物物理研究所 抗人cea的单克隆抗体，包含其的组合物，及其用途
EP4311863A3 (en) 2009-05-15 2024-04-10 University Health Network Compositions and methods for treating hematologic cancers targeting the sirp alpha- cd47 interaction
US20100297072A1 (en) * 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
EP2266588A1 (en) * 2009-06-04 2010-12-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Method for cancer therapy based on co-administration of a parovirus and a cytokine
CN104826106B (zh) * 2009-09-30 2019-01-11 斯隆凯特林防癌纪念中心 用于治疗癌症的组合免疫疗法
US20130017199A1 (en) * 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP2407177A1 (en) 2010-07-13 2012-01-18 Institut Gustave Roussy Adenovirus vaccine vectors
EP2383577A1 (en) 2010-04-30 2011-11-02 Deutsches Krebsforschungszentrum Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy
WO2011140284A2 (en) 2010-05-04 2011-11-10 Fred Hutchinson Cancer Research Center Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses
EP2739358B1 (en) 2011-08-01 2018-11-28 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
US20130071403A1 (en) * 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
US11155599B2 (en) 2012-02-02 2021-10-26 Board Of Regents, The University Of Texas System Adenoviruses expressing heterologous tumor-associated antigens
EP3010519B1 (en) 2013-06-18 2021-04-07 Dnatrix Inc. Oncolytic adenovirus for use in a treatment of brain cancer

Also Published As

Publication number Publication date
AU2013211871A1 (en) 2014-08-14
US20190269744A1 (en) 2019-09-05
CN104427992B (zh) 2017-12-19
HK1204577A1 (en) 2015-11-27
SG10201604654RA (en) 2016-07-28
CA2862390A1 (en) 2013-08-01
DK2806883T3 (da) 2019-07-22
AU2013211871B2 (en) 2017-12-14
KR20150008846A (ko) 2015-01-23
JP2015508156A (ja) 2015-03-16
BR112014018331A2 (enExample) 2017-06-20
WO2013112942A1 (en) 2013-08-01
JP2021103174A (ja) 2021-07-15
EP2806883B1 (en) 2019-04-24
JP2019066482A (ja) 2019-04-25
SG10201913784YA (en) 2020-03-30
US11065285B2 (en) 2021-07-20
BR112014018331A8 (pt) 2017-07-11
KR102081567B1 (ko) 2020-02-26
EP3578198A1 (en) 2019-12-11
US20140377221A1 (en) 2014-12-25
US10238698B2 (en) 2019-03-26
CN104427992A (zh) 2015-03-18
HK1208349A1 (en) 2016-03-04
EP2806883A1 (en) 2014-12-03
US20200330533A1 (en) 2020-10-22
AU2018201776A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
SG10201604654RA (en) Biomarkers and combination therapies using oncolytic virus and immunomodulation
IL236838A0 (en) Antibodies against dengue virus and uses thereof
IL235826A0 (en) Diazaspirocycloalkane and azaspirocycloalkane
GB2509400B (en) Rigid-stem lead-in-method and system
PL2855662T3 (pl) Rekombinowane mikroorganizmy i ich zastosowania
SG11201501254RA (en) Recombinant microorganisms and uses therefor
EP2925600A4 (en) WING AND ITS APPLICATION
GB201201100D0 (en) Polypeptides and methods
EP2761014A4 (en) RECOMBINANT PHAGE AND METHOD
IL237926A0 (en) Combinations and their uses
SG11201500111VA (en) Peptides and uses thereof
GB201321144D0 (en) Improved oncolytic viruses
SG10201701828WA (en) Peptides and their uses
GB201202016D0 (en) Noise and projection fairing
PT2914254T (pt) Terapias de combinação para tratar cancros quimiorresistentes
AP2014008113A0 (en) Pipeline and methods
EP2825548A4 (en) MODIFIED KISSPEPTIN PEPTIDES AND USES THEREOF
GB201211158D0 (en) Biomarkers and uses thereof
SG11201504482VA (en) Beta-hexosyl-transferases and uses thereof
ZA201501658B (en) Ventilator and blade therefor
GB201214769D0 (en) Methodsa and peptides
GB201222541D0 (en) Kiddibidet and pottibidet
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder
GB201210303D0 (en) Polypeptides and methods